Healthcare

Their financial positions differ considerably in scale, profitability and cash requirements, making revenue growth, margins,EarningsandLiquidityimportant measures through the remainder of 2026.

The quarterlyCash Flowreport shows operating, investing and financing activities all recorded at zero, both for the June 2026 quarter and on a year-to-date basis. Every major operating category typically reported in these filings, including research, manufacturing, marketing and staffing costs, showed zero activity and …

CSL is working through a business reset following significant FY26Impairmentand restructuring charges. Pro Medicus continues to expand its Visage imaging platform through long-term customer contracts, while Telix is building its commercial radiopharmaceutical portfolio and progressing additional diagnostic and therapeutic programs.

On 30 August 2026 Island told the market it had secured pivotal Marburg virus data supporting a United States Food and Drug Administration pathway for Galidesivir. Marburg is a filovirus with no approved treatment, and the regulatory route for such agents runs through the …

Joint and several voluntary administrators were appointed on 20 November 2024. Creditors voted at their second meeting on 27 February 2025 for the company to enter a deed of company arrangement, which was executed on 19 March. The deed provides the formal structure for …

Healius became the exclusive Australian pathology distributor for the Promarker portfolio in July 2026. Its network covers approximately 1,900 collection centres and existing referral channels. Healius will manage specimen collection, pathology distribution and commercial delivery to primary-care and specialist referrers. Proteomics International retains responsibility …

LTR Pharma (ASX:LTP) sits at the point where a clinical-stage story starts trying to become a commercial one. The company is developing intranasal drug delivery for men's health and other indications and spent FY2026 progressing its lead candidate through a Phase II study while …